Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foliglurax Pharmacodynamics in PD and Healthy Subjects
NCT04322227Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of foliglurax in Parkinson's disease (PD) (2 arms), sponsored by Lundbeck. Primary endpoints: Latency of EEG movement related desynchronization of the μ-oscillations at Day 7, Latency of EEG movement related synchronization of the beta-oscillations at Day 7 and 5 more. Started Jan 2020; status: terminated.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04322227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322227.